Tags

Type your tag names separated by a space and hit enter

sCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection.
Eur J Cardiothorac Surg. 2002 Sep; 22(3):368-72.EJ

Abstract

BACKGROUND

Combined inhibition of complement and leukocyte adhesion by sCR1sLe(X) reduces lung allograft dysfunction up to 24 h. In the present study its effect on graft function and acute rejection was evaluated up to 5 days after experimental transplantation.

METHODS

Orthotopic single left lung transplantation was performed in 35 male rats (Brown Norway to Fischer 344) after a total ischemic time of 20 h. Two groups were assessed after 1, 3, and 5 days post-transplant, respectively (n=5 per group and time point): controls vs. recipients which received 10 mg/kg sCR1sLe(X) 15 min prior to reperfusion. In addition, five animals received 10 mg/kg per day sCR1sLe(X) for 5 days. For blood gas analysis of the graft, the contralateral lung was occluded for 5 min to assess graft function. Lung grafts were flushed, and histological grading was performed in blinded fashion according to the International Society for Heart and Lung Transplantation criteria.

RESULTS

Graft PaO(2) in recipients treated with sCR1sLe(X) was superior on day 1 (383+/-118 vs. 56+/-15 mmHg; P<0.0001) and day 3 (446+/-48 vs. 231+/-108 mmHg; P<0.0001). Five days after transplantation, no difference in PaO(2) was found (61+/-28 vs. 83+/-31 mmHg; P=0.59). Repeated treatment with sCR1sLe(X) for 5 days did not improve PaO(2) (64+/-5 mmHg; P=0.65 vs. control; P=0.93 vs. sCR1sLe(X)). At any time point, there was no difference in the degree of rejection between groups.

CONCLUSIONS

In this model sCR1sLe(X) provided marked improvement of graft function up to 3 days, but inhibition of both complement system and selectin dependent leukocyte adhesion failed to protect against acute rejection.

Authors+Show Affiliations

Division of General Thoracic Surgery, University Hospital Berne, 3010 Berne, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12204725

Citation

Stammberger, Uz, et al. "SCR1sLe(X) Reduces Lung Allograft Ischemia-reperfusion Injury but Does Not Ameliorate Acute Rejection." European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery, vol. 22, no. 3, 2002, pp. 368-72.
Stammberger U, Hamacher J, Pache JC, et al. SCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection. Eur J Cardiothorac Surg. 2002;22(3):368-72.
Stammberger, U., Hamacher, J., Pache, J. C., & Schmid, R. A. (2002). SCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection. European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery, 22(3), 368-72.
Stammberger U, et al. SCR1sLe(X) Reduces Lung Allograft Ischemia-reperfusion Injury but Does Not Ameliorate Acute Rejection. Eur J Cardiothorac Surg. 2002;22(3):368-72. PubMed PMID: 12204725.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - sCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection. AU - Stammberger,Uz, AU - Hamacher,Jürg, AU - Pache,Jean-Claude, AU - Schmid,Ralph A, PY - 2002/9/3/pubmed PY - 2002/12/4/medline PY - 2002/9/3/entrez SP - 368 EP - 72 JF - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JO - Eur J Cardiothorac Surg VL - 22 IS - 3 N2 - BACKGROUND: Combined inhibition of complement and leukocyte adhesion by sCR1sLe(X) reduces lung allograft dysfunction up to 24 h. In the present study its effect on graft function and acute rejection was evaluated up to 5 days after experimental transplantation. METHODS: Orthotopic single left lung transplantation was performed in 35 male rats (Brown Norway to Fischer 344) after a total ischemic time of 20 h. Two groups were assessed after 1, 3, and 5 days post-transplant, respectively (n=5 per group and time point): controls vs. recipients which received 10 mg/kg sCR1sLe(X) 15 min prior to reperfusion. In addition, five animals received 10 mg/kg per day sCR1sLe(X) for 5 days. For blood gas analysis of the graft, the contralateral lung was occluded for 5 min to assess graft function. Lung grafts were flushed, and histological grading was performed in blinded fashion according to the International Society for Heart and Lung Transplantation criteria. RESULTS: Graft PaO(2) in recipients treated with sCR1sLe(X) was superior on day 1 (383+/-118 vs. 56+/-15 mmHg; P<0.0001) and day 3 (446+/-48 vs. 231+/-108 mmHg; P<0.0001). Five days after transplantation, no difference in PaO(2) was found (61+/-28 vs. 83+/-31 mmHg; P=0.59). Repeated treatment with sCR1sLe(X) for 5 days did not improve PaO(2) (64+/-5 mmHg; P=0.65 vs. control; P=0.93 vs. sCR1sLe(X)). At any time point, there was no difference in the degree of rejection between groups. CONCLUSIONS: In this model sCR1sLe(X) provided marked improvement of graft function up to 3 days, but inhibition of both complement system and selectin dependent leukocyte adhesion failed to protect against acute rejection. SN - 1010-7940 UR - https://www.unboundmedicine.com/medline/citation/12204725/sCR1sLe_X__reduces_lung_allograft_ischemia_reperfusion_injury_but_does_not_ameliorate_acute_rejection_ L2 - https://academic.oup.com/ejcts/article-lookup/doi/10.1016/s1010-7940(02)00355-x DB - PRIME DP - Unbound Medicine ER -